Table 1.
Clinical and biological characteristics of the 41 AML patients. Unless otherwise stated the results are presented as the number of patients (for additional details see Table S1).
| Sex and Age (n = 41) | Karyotype/Cytogenetic Abnormalities | ||
|---|---|---|---|
| Males/females | 22/19 | Normal | 21 |
| Age (years; median/range) | 70/18–87 | Favorable | 4 |
| Intermediate | 9 | ||
| Predisposition/previous disease | Adverse | 4 | |
| Previous chronic myeloid neoplasia | 1 | Not tested | 3 |
| Myelodysplastic syndrome | 8 | ||
| Relapsed AML | 3 | Flt3 status | |
| Chemotherapy related | 0 | ITD | 14 |
| Wild type | 19 | ||
| Morphology/FAB classification | Not tested | 8 | |
| M0/M1 | 17 | ||
| M2 | 8 | NPM1 status | |
| M4/M5 | 16 | Insertion | 14 |
| M6/M7 | 0 | Insertion + Flt3-ITD | 9 |
| Wild type | 20 | ||
| CD34 positive | 22 | Not tested | 7 |
Abbreviations: FAB, French-American-British; ITD, internal tandem duplication.